Eddingpharm announced today that it has reached an exclusive agreement with Roche China, whereby Eddingpharm will hold the exclusive rights to promote and distribute Roche’s Recormon®, a recombinant human erythropoietin product, in mainland China beginning on January 31, 2018.

Under the terms of the agreement, the product will continue to be marketed as Roche Recormon® and Roche will continue to manufacture the drug in accordance with its global product quality standards.

As the only recombinant human erythropoietin-βproduct, Recormon was approved to be launched to the Chinese market in 1995. It has become a highly recognized recombinant human erythropoietin brand by medical professionals, and was listed in the national health insurance catalogue in 2017. Over the past two decades, Recormon helped tens of thousands of Chinese patients with renal anemia.

“We are excited to partner with Roche and we are very proud to continue providing patients with this high quality product”, said Xin Ni, CEO of Eddingpharm. “Eddingpharm aims to link the world's high-quality drugs with Chinese clinicians and patients. The strategic cooperation with Roche has strengthened the core competitiveness of Eddingpharm in the field of Nephrology and other severe diseases treatment. At the same time, we will use our operating experience in the pharmaceutical industry and a wide distribution network throughout the country to further expand the coverage of Recormon in the Chinese market, so that it can benefit more Chinese patients.”